The global market for Prostate Cancer Hormone Therapy was estimated to be worth US$ 11140 million in 2023 and is forecast to a readjusted size of US$ 18850 million by 2030 with a CAGR of 7.7% during the forecast period 2024-2030

Prostate Cancer Hormone Therapy - Market

Hormone therapy for prostate cancer is a treatment that stops the hormone testosterone either from being made or from reaching prostate cancer cells. Most prostate cancer cells rely on testosterone to grow. Hormone therapy causes prostate cancer cells to die or to grow more slowly.

The prostate cancer hormone therapy market is evolving rapidly, driven by factors like:

Rising prostate cancer diagnosis: Prostate cancer remains the most common cancer among men in many countries. Early diagnosis and improved treatment options have contributed to increasing survival rates, fueling market growth.

Shifting treatment trends: Hormone therapy, which aims to lower testosterone levels and starve prostate cancer cells, is a cornerstone treatment for advanced and recurrent prostate cancer. Advancements in medication and targeted therapies are shaping the market landscape.

Personalized medicine: Growing understanding of cancer genomics and individual variations in response to therapy is leading to the development of personalized treatment plans, including targeted hormone therapies with fewer side effects.

Drug landscape: A variety of drugs belonging to different classes, like GnRH agonists, antagonists, and androgen receptor inhibitors, cater to diverse patient needs and treatment stages.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Hormone Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Prostate Cancer Hormone Therapy by region & country, by Type, and by Application.

The Prostate Cancer Hormone Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Hormone Therapy.

Market Segmentation

Scope of Prostate Cancer Hormone Therapy - Market Report

Report Metric	Details
Report Name	Prostate Cancer Hormone Therapy - Market
Forecasted market size in 2030	US$ 18850 million
CAGR	7.7%
Forecasted years	2024 - 2030
Segment by Type:	Tablet Injection
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Astellas, Johnson & Johnson, AstraZeneca, Bayer, Merck, Tolmar, Zoladex, Ferring Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, CTTQ
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Prostate Cancer Hormone Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Prostate Cancer Hormone Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Prostate Cancer Hormone Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Prostate Cancer Hormone Therapy - Market size in 2030?

Ans: The Prostate Cancer Hormone Therapy - Market size in 2030 will be US$ 18850 million.

Who are the main players in the Prostate Cancer Hormone Therapy - Market report?

Ans: The main players in the Prostate Cancer Hormone Therapy - Market are Pfizer, Astellas, Johnson & Johnson, AstraZeneca, Bayer, Merck, Tolmar, Zoladex, Ferring Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, CTTQ

What are the Application segmentation covered in the Prostate Cancer Hormone Therapy - Market report?

Ans: The Applications covered in the Prostate Cancer Hormone Therapy - Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Prostate Cancer Hormone Therapy - Market report?

Ans: The Types covered in the Prostate Cancer Hormone Therapy - Market report are Tablet, Injection

1 Market Overview

1.1 Prostate Cancer Hormone Therapy Product Introduction

1.2 Global Prostate Cancer Hormone Therapy Market Size Forecast

1.3 Prostate Cancer Hormone Therapy Market Trends & Drivers

1.3.1 Prostate Cancer Hormone Therapy Industry Trends

1.3.2 Prostate Cancer Hormone Therapy Market Drivers & Opportunity

1.3.3 Prostate Cancer Hormone Therapy Market Challenges

1.3.4 Prostate Cancer Hormone Therapy Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Prostate Cancer Hormone Therapy Players Revenue Ranking (2023)

2.2 Global Prostate Cancer Hormone Therapy Revenue by Company (2019-2024)

2.3 Key Companies Prostate Cancer Hormone Therapy Manufacturing Base Distribution and Headquarters

2.4 Key Companies Prostate Cancer Hormone Therapy Product Offered

2.5 Key Companies Time to Begin Mass Production of Prostate Cancer Hormone Therapy

2.6 Prostate Cancer Hormone Therapy Market Competitive Analysis

2.6.1 Prostate Cancer Hormone Therapy Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Prostate Cancer Hormone Therapy Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Hormone Therapy as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Tablet

3.1.2 Injection

3.2 Global Prostate Cancer Hormone Therapy Sales Value by Type

3.2.1 Global Prostate Cancer Hormone Therapy Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Prostate Cancer Hormone Therapy Sales Value, by Type (2019-2030)

3.2.3 Global Prostate Cancer Hormone Therapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Others

4.2 Global Prostate Cancer Hormone Therapy Sales Value by Application

4.2.1 Global Prostate Cancer Hormone Therapy Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Prostate Cancer Hormone Therapy Sales Value, by Application (2019-2030)

4.2.3 Global Prostate Cancer Hormone Therapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Prostate Cancer Hormone Therapy Sales Value by Region

5.1.1 Global Prostate Cancer Hormone Therapy Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Prostate Cancer Hormone Therapy Sales Value by Region (2019-2024)

5.1.3 Global Prostate Cancer Hormone Therapy Sales Value by Region (2025-2030)

5.1.4 Global Prostate Cancer Hormone Therapy Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Prostate Cancer Hormone Therapy Sales Value, 2019-2030

5.2.2 North America Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Prostate Cancer Hormone Therapy Sales Value, 2019-2030

5.3.2 Europe Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Prostate Cancer Hormone Therapy Sales Value, 2019-2030

5.4.2 Asia Pacific Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Prostate Cancer Hormone Therapy Sales Value, 2019-2030

5.5.2 South America Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Prostate Cancer Hormone Therapy Sales Value, 2019-2030

5.6.2 Middle East & Africa Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value

6.3 United States

6.3.1 United States Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.3.2 United States Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.4.2 Europe Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.5.2 China Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.5.3 China Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.6.2 Japan Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.7.2 South Korea Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.8.2 Southeast Asia Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Prostate Cancer Hormone Therapy Sales Value, 2019-2030

6.9.2 India Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

6.9.3 India Prostate Cancer Hormone Therapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer

7.1.1 Pfizer Profile

7.1.2 Pfizer Main Business

7.1.3 Pfizer Prostate Cancer Hormone Therapy Products, Services and Solutions

7.1.4 Pfizer Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Recent Developments

7.2 Astellas

7.2.1 Astellas Profile

7.2.2 Astellas Main Business

7.2.3 Astellas Prostate Cancer Hormone Therapy Products, Services and Solutions

7.2.4 Astellas Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.2.5 Astellas Recent Developments

7.3 Johnson & Johnson

7.3.1 Johnson & Johnson Profile

7.3.2 Johnson & Johnson Main Business

7.3.3 Johnson & Johnson Prostate Cancer Hormone Therapy Products, Services and Solutions

7.3.4 Johnson & Johnson Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.3.5 AstraZeneca Recent Developments

7.4 AstraZeneca

7.4.1 AstraZeneca Profile

7.4.2 AstraZeneca Main Business

7.4.3 AstraZeneca Prostate Cancer Hormone Therapy Products, Services and Solutions

7.4.4 AstraZeneca Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.4.5 AstraZeneca Recent Developments

7.5 Bayer

7.5.1 Bayer Profile

7.5.2 Bayer Main Business

7.5.3 Bayer Prostate Cancer Hormone Therapy Products, Services and Solutions

7.5.4 Bayer Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.5.5 Bayer Recent Developments

7.6 Merck

7.6.1 Merck Profile

7.6.2 Merck Main Business

7.6.3 Merck Prostate Cancer Hormone Therapy Products, Services and Solutions

7.6.4 Merck Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.6.5 Merck Recent Developments

7.7 Tolmar

7.7.1 Tolmar Profile

7.7.2 Tolmar Main Business

7.7.3 Tolmar Prostate Cancer Hormone Therapy Products, Services and Solutions

7.7.4 Tolmar Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.7.5 Tolmar Recent Developments

7.8 Zoladex

7.8.1 Zoladex Profile

7.8.2 Zoladex Main Business

7.8.3 Zoladex Prostate Cancer Hormone Therapy Products, Services and Solutions

7.8.4 Zoladex Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.8.5 Zoladex Recent Developments

7.9 Ferring Pharmaceuticals

7.9.1 Ferring Pharmaceuticals Profile

7.9.2 Ferring Pharmaceuticals Main Business

7.9.3 Ferring Pharmaceuticals Prostate Cancer Hormone Therapy Products, Services and Solutions

7.9.4 Ferring Pharmaceuticals Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.9.5 Ferring Pharmaceuticals Recent Developments

7.10 Jiangsu Hengrui Pharmaceuticals

7.10.1 Jiangsu Hengrui Pharmaceuticals Profile

7.10.2 Jiangsu Hengrui Pharmaceuticals Main Business

7.10.3 Jiangsu Hengrui Pharmaceuticals Prostate Cancer Hormone Therapy Products, Services and Solutions

7.10.4 Jiangsu Hengrui Pharmaceuticals Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments

7.11 CTTQ

7.11.1 CTTQ Profile

7.11.2 CTTQ Main Business

7.11.3 CTTQ Prostate Cancer Hormone Therapy Products, Services and Solutions

7.11.4 CTTQ Prostate Cancer Hormone Therapy Revenue (US$ Million) & (2019-2024)

7.11.5 CTTQ Recent Developments

8 Industry Chain Analysis

8.1 Prostate Cancer Hormone Therapy Industrial Chain

8.2 Prostate Cancer Hormone Therapy Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Prostate Cancer Hormone Therapy Sales Model

8.5.2 Sales Channel

8.5.3 Prostate Cancer Hormone Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Ferring Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals

CTTQ

List of Tables

Table 1. Prostate Cancer Hormone Therapy Market Trends

Table 2. Prostate Cancer Hormone Therapy Market Drivers & Opportunity

Table 3. Prostate Cancer Hormone Therapy Market Challenges

Table 4. Prostate Cancer Hormone Therapy Market Restraints

Table 5. Global Prostate Cancer Hormone Therapy Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Prostate Cancer Hormone Therapy Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Prostate Cancer Hormone Therapy Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Prostate Cancer Hormone Therapy Product Type

Table 9. Key Companies Time to Begin Mass Production of Prostate Cancer Hormone Therapy

Table 10. Global Prostate Cancer Hormone Therapy Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Hormone Therapy as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Prostate Cancer Hormone Therapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Prostate Cancer Hormone Therapy Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Prostate Cancer Hormone Therapy Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Prostate Cancer Hormone Therapy Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Prostate Cancer Hormone Therapy Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Prostate Cancer Hormone Therapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Prostate Cancer Hormone Therapy Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Prostate Cancer Hormone Therapy Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Prostate Cancer Hormone Therapy Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Prostate Cancer Hormone Therapy Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Prostate Cancer Hormone Therapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Prostate Cancer Hormone Therapy Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Prostate Cancer Hormone Therapy Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Prostate Cancer Hormone Therapy Sales Value by Region (2019-2024) & (%)

Table 27. Global Prostate Cancer Hormone Therapy Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Basic Information List

Table 32. Pfizer Description and Business Overview

Table 33. Pfizer Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 34. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Pfizer (2019-2024)

Table 35. Pfizer Recent Developments

Table 36. Astellas Basic Information List

Table 37. Astellas Description and Business Overview

Table 38. Astellas Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 39. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Astellas (2019-2024)

Table 40. Astellas Recent Developments

Table 41. Johnson & Johnson Basic Information List

Table 42. Johnson & Johnson Description and Business Overview

Table 43. Johnson & Johnson Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 44. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Johnson & Johnson (2019-2024)

Table 45. Johnson & Johnson Recent Developments

Table 46. AstraZeneca Basic Information List

Table 47. AstraZeneca Description and Business Overview

Table 48. AstraZeneca Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 49. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of AstraZeneca (2019-2024)

Table 50. AstraZeneca Recent Developments

Table 51. Bayer Basic Information List

Table 52. Bayer Description and Business Overview

Table 53. Bayer Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 54. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Bayer (2019-2024)

Table 55. Bayer Recent Developments

Table 56. Merck Basic Information List

Table 57. Merck Description and Business Overview

Table 58. Merck Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 59. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Merck (2019-2024)

Table 60. Merck Recent Developments

Table 61. Tolmar Basic Information List

Table 62. Tolmar Description and Business Overview

Table 63. Tolmar Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 64. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Tolmar (2019-2024)

Table 65. Tolmar Recent Developments

Table 66. Zoladex Basic Information List

Table 67. Zoladex Description and Business Overview

Table 68. Zoladex Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 69. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Zoladex (2019-2024)

Table 70. Zoladex Recent Developments

Table 71. Ferring Pharmaceuticals Basic Information List

Table 72. Ferring Pharmaceuticals Description and Business Overview

Table 73. Ferring Pharmaceuticals Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 74. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Ferring Pharmaceuticals (2019-2024)

Table 75. Ferring Pharmaceuticals Recent Developments

Table 76. Jiangsu Hengrui Pharmaceuticals Basic Information List

Table 77. Jiangsu Hengrui Pharmaceuticals Description and Business Overview

Table 78. Jiangsu Hengrui Pharmaceuticals Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 79. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of Jiangsu Hengrui Pharmaceuticals (2019-2024)

Table 80. Jiangsu Hengrui Pharmaceuticals Recent Developments

Table 81. CTTQ Basic Information List

Table 82. CTTQ Description and Business Overview

Table 83. CTTQ Prostate Cancer Hormone Therapy Products, Services and Solutions

Table 84. Revenue (US$ Million) in Prostate Cancer Hormone Therapy Business of CTTQ (2019-2024)

Table 85. CTTQ Recent Developments

Table 86. Key Raw Materials Lists

Table 87. Raw Materials Key Suppliers Lists

Table 88. Prostate Cancer Hormone Therapy Downstream Customers

Table 89. Prostate Cancer Hormone Therapy Distributors List

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

Table 93. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Prostate Cancer Hormone Therapy Product Picture

Figure 2. Global Prostate Cancer Hormone Therapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 4. Prostate Cancer Hormone Therapy Report Years Considered

Figure 5. Global Prostate Cancer Hormone Therapy Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Prostate Cancer Hormone Therapy Revenue in 2023

Figure 7. Prostate Cancer Hormone Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Tablet Picture

Figure 9. Injection Picture

Figure 10. Global Prostate Cancer Hormone Therapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Prostate Cancer Hormone Therapy Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital

Figure 13. Product Picture of Clinic

Figure 14. Product Picture of Others

Figure 15. Global Prostate Cancer Hormone Therapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Prostate Cancer Hormone Therapy Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Prostate Cancer Hormone Therapy Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Prostate Cancer Hormone Therapy Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Prostate Cancer Hormone Therapy Sales Value (%), (2019-2030)

Figure 28. United States Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 34. China Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 36. China Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 46. India Prostate Cancer Hormone Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Prostate Cancer Hormone Therapy Sales Value by Type (%), 2023 VS 2030

Figure 48. India Prostate Cancer Hormone Therapy Sales Value by Application (%), 2023 VS 2030

Figure 49. Prostate Cancer Hormone Therapy Industrial Chain

Figure 50. Prostate Cancer Hormone Therapy Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions